Brise Pharmaceuticals announces global license agreement with AbbVie to advance next-generation migraine therapies

ABBV•2026-11-02

Brise Pharmaceuticals announced a global license agreement with AbbVie for next-generation migraine therapies, with potential deal value of up to US$757 million plus royalties on future sales.

1. License agreement

Brise Pharmaceuticals announced a global license agreement with AbbVie to advance next-generation migraine therapies. The potential deal value could reach up to US$757 million, plus royalties on future sales.

Brise Pharmaceuticals announces global license agreement with AbbVie to advance next-generation migraine therapies

1. License agreement

Related News

JLL advises Nuveen on $445.5 million acquisition of 13-property Western US retail portfolio

Pphc announces new $105 million senior secured credit facility

Colony Bankcorp announces completion of merger with First Reliance Bancshares

Nasdaq trade halt continues; reason not available at 9:40 a.m.

ECB flags AI valuations, bond stress and fund losses as main risks